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Abstract
Background: There has been an increasing number of diagnosed cases of Chlamydia trachomatis in many countries, in 
particular among young people. The present study was based on a growing request to examine urine as a 
supplementary or primary specimen in screening for Chlamydia trachomatis in women, with the Becton Dickinson 
ProbeTec (BDPT) Strand Displacement Assay (SDA). Urine samples may be particularly important in screening young 
people who are asymptomatic.
Methods: A total of 603 women aged 15 and older were enrolled from the Sexually Transmitted Infection (STI) clinic at 
Haukeland University Hospital, Norway, in 2007. Only 31 women were older than 35 years. Cervical swabs and urine 
samples were tested with BDPT for all participants. In cases of discrepant test results from a given patient, both samples 
were retested by Cobas TaqManCT and a Polymerase Chain Reaction (PCR)-method (in-house). Prevalence of C. 
trachomatis, sensitivity, and specificity were estimated by latent class analysis using all test results available. Bootstrap 
BC confidence intervals (10 000 computations) were estimated for sensitivity and specificity, and their differences in 
cervix vs. urine tests.
Results: A total of 1809 specimens were collected from 603 patients. 80 women (13.4%) were positive for C. 
trachomatis. Among these, BDPT identified 72 and 73 as positive in cervix and urine samples, respectively. Of the 523 C. 
trachomatis negative women, BDPT identified 519 as negative based on cervical swabs, and 514 based on urine 
samples. Sensitivity for cervical swabs and urine samples with the BDPT were 89.0% (95% CI 78.8, 98.6) and 90.2% (95% 
CI 78.1, 95.5), respectively. The corresponding values for specificity were 99.2% (95% CI 98.3, 100) and 98.3% (95% CI 
96.4, 100).
Conclusions: This study indicates that urine specimens are adequate for screening high-risk groups for C. trachomatis 
by the SDA method (BDPT). Such an approach may facilitate early detection and treatment of the target groups for 
screening, and be cost-effective for patients and the health services.
Background
An increased number of diagnosed cases of C. trachomatis
in younger age groups calls for an intensified effort to pre-
vent infections, and complications such as pelvic inflamma-
tory disease and infertility. In 2007, a total of 22 847
infections were reported in Norway, constituting 8.4% of
the individuals tested. Of those infected, 61% were women
[1]. Of the total number of reported infections, 68% were
younger than 25 years (40% were between 20-24 years, and
28% between 15-19 years). The greatest increase in the
number of infections was seen among 15-19 year-olds.
Similar trends are reported from Sweden, Denmark, Eng-
land and the US [2-7].
Most C. trachomatis infections are asymptomatic. Thus,
motivation for testing is based on the patients' knowledge of
transmission and consequences of infection, as well as per-
ceived barriers. Screening of asymptomatic populations is
facilitated by the use of minimally invasive or non-invasive
sampling. Most individuals tested for C. trachomatis in
Norway are above 24 years, but the prevalence rates are
significantly higher between 15 and 24 years [1]. Thus, it is
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important to offer sampling procedures which lower the
threshold for screening and diagnostic testing in the
younger age groups as well as being cost-effective.
Gynaecological examination is generally considered a main
barrier in recruiting young women for testing [8].
Endocervical swabs, vaginal swabs and urine are poten-
tial specimens for testing women. The diagnostic value of
each of these specimens may vary according to the popula-
tion tested and laboratory method used. Several laboratory
methods are available for direct detection of C. trachoma-
tis, such as cell culture, immunofluorescense microscopy
and enzyme immunoassays (EIA). At present, nucleic acid
amplification tests (NAATs) provide unsurpassed sensitiv-
ity and high specificity when applied on cervical and ure-
thral swabs and male urine samples. NAATs target species-
specific sequences of DNA for detection of pathogens. For
the commonly used polymerase chain reaction (PCR)
method, there is evidence that testing of female and male
urine is equivalent to cervical and urethral swabs, respec-
tively, in terms of sensitivity and specificity [9-11]. Vaginal
swabs are not validated for use by the manufacturers of the
two most commonly used NAATs in Norway. The BDPro-
beTec™ Chlamydia trachomatis Amplified DNA Assay
(BDPT) utilizes a strand displacement amplification (SDA)
method coupled with a fluorescent energy transfer (ET)
measurement in detecting the amplified product. For this
method as well, the sensitivity in male urine samples is
comparable to that of urethral swabs. However, studies
based on urine samples from women have shown lower
sensitivity compared to endocervical swabs [12,13], a
potential impediment for testing, especially for screening
purposes.
The aim of the present study was to evaluate the perfor-
mance of the SDA method in detection of C. trachomatis in
cervical swabs and urine samples in a female population.
This was achieved by comparing discrepant results in the
BD SDA to a composite reference standard defined by
results from two other NAATs, the Cobas TaqMan CT PCR
and an in-house PCR targeting genomic C. trachomatis
DNA.
Methods
Ethics
The study was approved by the regional ethics committee
and the involved institutions. The women were included on
the basis of verbal consent, after receiving oral and written
information about the study, and their right to receive stan-
dard testing and treatment without taking part in the study.
Patient information was collected and stored at the hospital.
All participants received the standard testing, and in addi-
tion an extra cervical swab and a urine sample were col-
lected at the time of consultation. Participation was not
expected to burden the women.
Study population
Women attending the STI clinic at Haukeland University
Hospital, Bergen, Norway, were enrolled in the study. This
clinic has a drop-in policy, providing testing of anyone wor-
ried about C. trachomatis or other sexually transmitted
infections (STI), without an appointment or referral during
daytime opening hours. Both examination and treatment are
free of charge for the patient. A total of about 2000 women
are tested for C. trachomatis in this clinic every year.
Among these, 13% are positive for C. trachomatis.
Participants
All women (n = 618) tested for C. trachomatis at the STI
clinic in the period from January 2nd to June 15th, 2007,
were asked to participate. Reasons for contacting the clinic
were symptoms, contact tracing or unprotected sex. A med-
ical doctor evaluated the need for C. trachomatis testing.
Exclusion criteria were pregnancy or the use of antibiotics
during the previous 21 days.
Specimen collection
Participants received standard clinical examination, testing
and treatment. Two cervical swabs were collected during
the examination, and the patients also delivered a urine
sample. Vaginal swabs were not collected since BDPT is
not approved for this specimen.
Urine samples were collected according to guidelines
(first catch urine: FCU, mid-stream, at least two hours after
previous urination, at least 10 - 20 ml urine). Cervical
swabs were collected by the doctors at the clinic, based on
regular procedures for speculum examination and using the
manufacturer's collection kits. After cleaning of the cervix
with the dry swab provided in the kit, two swabs were col-
lected for each patient. One swab was for the BDPT
medium, and one for Roche CT. The two swabs were col-
lected first and second alternately, to minimize the effect of
sample variation. The specimens were transported to the
diagnostic laboratory at the microbiology department on the
same campus. The urine specimens were transported with-
out any added transport medium, and refrigerated and
examined within 48 hours with BDPT, and within 7 days
with Cobas TaqMan CT and in-house PCR. The cervical
swabs were stored at room temperature and tested within 48
hours with BDPT and within 10 days with Cobas TaqMan
CT and in-house PCR. When necessary, additional tests for
other STIs were collected after the tests above. Patients
were tested for Trichomonas vaginalis, Herpes simplex 1
and 2, Neisseria gonorrhoea, HIV, Hepatitis B and C, and
Treponema pallidum when indicated.
Testing of specimens
Cervical swabs and urine samples were tested with BDPT
for all participants, according to the manufacturers' guide-
lines and standard routines at the laboratory. Internal valida-Haugland et al. BMC Women's Health 2010, 10:9
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tion was carried out by adding an amplifying control (AC)
for all the examined tests.
In cases of discrepant test results for the cervical swab
and urine samples from a given patient, both samples were
retested by Cobas TaqManCT in the same laboratory, and
also tested by a PCR-method (in-house) developed at the
University Hospital of North Norway.
A woman was considered C. trachomatis positive if both
FCU and the cervical swab were positive by the SDA
method (BDPT), or if one of the specimens tested positive
by the SDA method and at least one specimen was positive
for the Cobas TaqManCT or the in-house PCR.
Laboratory methods
The BD ProbeTec™ (Chlamydia trachomatis amplified
DNA assay, Becton, Dickinson and Company, Sparks, MD
USA) utilizes homogeneous Strand Displacement Amplifi-
cation (SDA) technology as the amplification method and
fluorescent energy transfer (ET) as the detection method to
test for the presence of C. trachomatis. The test is based on
the simultaneous amplification and detection of target
DNA, using amplification primers directed against plasmid
DNA and a fluorescent labelled detector probe. The
COBAS TaqMan CT Test (Roche Diagnostics GmbH,
Mannheim, Germany) is based on manual specimen prepa-
ration to obtain C. trachomatis DNA, followed by PCR
amplification of target DNA. The PCR uses C. trachomatis-
specific complementary primers directed against cryptic
plasmid DNA. The result is obtained by detection of a
cleaved dual fluorescent dye-labelled oligonucleotide
detection probe that permits the detection of C. trachomatis
target amplified product (amplicon) and C. trachomatis
Internal Control DNA, which is amplified and detected
simultaneously with the specimen. Both methods were per-
formed according to the manufacturer's instructions. Both
BDPT and the in-house PCR were able to detect the new
variant of C. trachomatis.
Statistical analysis
Descriptive statistics included frequency distributions.
Prevalence of C. trachomatis and sensitivity and specificity
of the BDPT cervix and urine samples were estimated by
latent class analysis using all test results available, indepen-
dent of the above classification of discrepant results [14].
Bootstrap BCa confidence intervals [15], a procedure that
does not make specific distributional assumptions, were
computed for sensitivity and specificity, and their differ-
ences in cervical vs urine tests. A total of 10 000 bootstrap
computations were undertaken.
All tests were two-sided, and p-values below 0.05 were
considered significant. Descriptive analyses used SPSS ver-
sion 15.0 (SPSS Inc, Chicago, IL, USA). Latent class anal-
ysis used the package poLCA[15] and bootstrap BCa
intervals were computed in the package boot in R (The R
Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 1809 specimens were collected from 603
patients, all of which were included in the statistical data
analyses. Among the participants, 80 women (13%) were
15-19 years old, 235 (39%) were 20-22 years, 154 (26%)
were 23-25 years, 63 (10%) were 26-29 years, 39 (7%)
were 30-34 years. The remaining 32 women were between
35 and 56 years. A total of 15 women were excluded; ten
due to lack of an adequate urine sample, three due to use of
antibiotics, and two because of inadequate gynaecological
examination (one woman had painful genital herpes, one
did not want an examination). None of the attending
women were excluded due to pregnancy.
No inhibitory effect was observed in the samples in any
of the methods. Based on the definition of a positive test (C.
trachomatis positive in BDPT in both urine and cervical
swab or one positive test in any two specimens in two out of
three methods applied), 80 women (13.4%) were defined as
positive for C. trachomatis, and 523 were negative. Of the
80 C. trachomatis positives, BDPT identified 72 and 73 as
positive in cervix and urine samples, respectively. Of the
523 C. trachomatis negative women, BDPT identified 519
as negative based on cervical swabs, and 514 based on
urine samples.
Three of the C. trachomatis positive women were diag-
nosed with genital condyloma acuminata. None were diag-
nosed with other STI. Of the C. trachomatis negative
women 35 had condyloma acuminata, seven genital herpes
and one trichomonas vaginalis. Two were hepatitis C posi-
tive.
Table 1 shows the results of the SDA method according
to specimen. BDPT gave discrepant results for 28 patients,
and their samples were subsequently tested with the two
PCR methods.
Table 2 shows the results of the additional tests and the
conclusion (presence or absence of C. trachomatis infec-
tion) for these 28 women. For 15 C. trachomatis positive
women, C. trachomatis was detected in either FCU (seven
women) or the cervical swab (eight women) by the SDA
method.
Based on the latent class analyses the estimated preva-
lence of C. trachomatis was 13.4%. There were no signifi-
cant differences in diagnostic outcome between cervical
swabs and urine samples using the SDA technique. Esti-
mates including confidence intervals are summarised in
Table 3.
Positive and negative predictive values (PPV and NPV)
were estimated based on prevalence, sensitivity, and speci-
ficity. For cervical swabs the PPV and NPV were 94.7%
and 99.2%, respectively. The corresponding values for
urine samples were 89.0% and 98.3%Haugland et al. BMC Women's Health 2010, 10:9
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Discussion
This study shows that the SDA method has comparable sen-
sitivity and specificity in cervical swabs and urine speci-
mens for C. trachomatis testing. This suggests that urine is
an acceptable alternative to cervical swabs in the studied
female sample. The confidence interval for difference in
sensitivity was broad, and differences in sensitivity in cer-
vix and urine samples cannot be ruled out. On the other
hand, substantial differences in specificity between the two
tests are unlikely. Both the present and previous studies
[16] show that some infected individuals are positive only
with FCU. To maximize diagnostic sensitivity, both urine
and cervical swabs could be sampled when possible.
The results are based on testing of women in a university
hospital STI clinic and laboratory, with well-established
procedures for testing and handling specimens. The sam-
pling was carried out by specialist medical doctors. The
limitations of this study are mainly related to the potential
bias of a discrepant analysis approach. Additional tests with
COBAS TaqMan CT Test and the in-house PCR were car-
ried out for discrepant tests only. The aim of the present
study was to evaluate the performance of the SDA method
in detection of C. trachomatis in cervical swabs and urine
samples, not to compare or evaluate the three methods. The
differences in sensitivity and specificity are expected to be
small when the frequency of discordant results is relatively
low [14]. Three sets of tests for all patients would have
given a stronger design resulting in higher precision in our
estimates, as there is a possibility of a C. trachomatis diag-
nosis, even if both urine and the cervical swabs are negative
in the SDA test. A possible bias in our latent class etimates
might occur if the additional Cobas TaqMan CT and PCR
tests are systematically different when the BDPT tests are
concordant, respectively discordant. We do not expect that
such systematic differences are likely.
Previous studies have shown a higher sensitivity of the
SDA method for cervical swabs than for FCU [12,13]. Our
study suggests that urine may be used for screening, as
there was no significant difference between the two speci-
mens. From a clinical perspective, the positive predictive
value (PPV) of a test determines the proportion of patients
with positive test results who are correctly diagnosed as
having the infection. In the present study 94.7% were diag-
nosed correctly by cervical swabs and 89.0% based on
FCU. Thus, both urine and cervical samples are useful for
diagnostic purposes.
The proportion of positive tests in the studied population
is expected to be higher than in the general population, as
the sample is recruited from a STI clinic. However, several
Table 2: Results of the BD Probe Tec ET, Cobas Taq Man and in-house PCR for 28 women tested by all three methods
Number of 
same inter-
method 
pattern
BD Probe tec Cobas TM In-house PCR Overall 
result
urine cervix urine cervix urine cervix
1 -+++- -+
4 -+-----
4 -++++++
1 -+-+-++
1 -+-++-+
1 +-+-+-+
2 +-+++-+
1 +-++-++
9 +------
4 +-+-+-+
Table 1: Results of testing for Chlamydia trachomatis by BD 
ProbeTecET according to specimen for a total of 603 
women
Number of women, N (%)
Cervix neg, urine neg 510 (84.6)
Cervix neg, urine pos 17 (2.8)
Cervix pos, urine neg 11 (1.8)
Cervix pos, urine pos 65 (10.8)
Total 603 (100)Haugland et al. BMC Women's Health 2010, 10:9
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studies suggest that the target populations for screening,
such as young people and individuals with multiple or fre-
quent change of sexual partners, have comparable or higher
prevalence rates [17,18]. In populations with lower preva-
lence rates, i.e. pregnant women with C. trachomatis infec-
tion rates of 3-5%, PPV would be significantly lower. Thus,
a greater proportion of women would receive false positive
tests than in high prevalence groups [19]. On this basis,
confirmation of a positive test, by sampling both urine and
cervical swabs and retesting of positive tests, should be
considered in screening low-prevalence groups.
Early detection and treatment of C. trachomatis may
reduce complications resulting from untreated infections.
From a public health point of view, current recommenda-
tions emphasise that high risk groups should be approached
and offered non-invasive testing. The present findings are
important to facilitate such intervention. Studies of cost-
effectiveness also support examination of FCU in screening
high-risk populations [20].
Previous studies have argued for self obtained vaginal
swabs in screening for C. trachomatis in female popula-
tions [21-23]. Blake demonstrated higher sensitivity and
specificity for self obtained vaginal swabs when compared
to first cast urine and endocervical samples [21]. Schachter
and colleagues found that vaginal swabs identified as many
infected patients as cervical swabs, and more than urine
samples. These studies have also demonstrated cost-effec-
tiveness. Michel (2007) recommended vaginal swabs based
on the findings that FCU had lower organism load than vag-
inal swabs in asymptomatic women [22]. However, vaginal
swabs are not validated by the manufacturers of the two
most commonly used NAATs in Norway.
For boys, FCU is the sample of choice. In advocating
screening of asymptomatic young people, there may be
advantages in promoting the same methods of sampling
both for boys and girls. Earlier research showed that testing
strategies targeting asymptomatic individuals in established
community and clinical settings, are more likely to yield
high acceptance rates than home based approaches [24].
Testing of FCU may allow for express visit options for cli-
ents with low risk of other STIs, increasing the efficiency of
outpatient clinics [24-26].
In promoting screening among high-risk groups, it is
important that information is linked to balanced informa-
tion about other sexually transmitted infections. Fear of the
consequences of C. trachomatis may promote condom use.
Thus, it is important to avoid a decrease in use of condoms
due to a perception of easy testing and treatment for C. tra-
chomatis.
Conclusions
This study suggests that urine specimens are comparable to
cervical swabs in screening high-risk groups for C. tracho-
matis by the SDA method (BDPT). Such an approach may
facilitate early detection and treatment of the target groups
for screening, and be cost-effective for patients and the
health services. Studies with additional tests performed for
a larger proportion of the patients, may reduce the uncer-
tainty related to differences in test sensitivity. More
research is needed to determine the usefulness of urine sam-
ples in testing low-prevalence populations.
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